• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

影响表皮生长因子受体不可逆抑制的因素及手性对共价结合的影响。

Factors affecting irreversible inhibition of EGFR and influence of chirality on covalent binding.

作者信息

Morese Pasquale A, Ahmad Ayaz, Martin Mathew P, Noble Richard A, Pintar Sara, Wang Lan Z, Xu Shangze, Lister Andrew, Ward Richard A, Bronowska Agnieszka K, Noble Martin E M, Stewart Hannah L, Waring Michael J

机构信息

Cancer Research Horizons Newcastle Drug Discovery Unit, Chemistry, School of Natural and Environmental Sciences, Bedson Building, Newcastle University, Newcastle upon Tyne, UK.

Chemistry, School of Natural and Environmental Sciences, Bedson Building, Newcastle University, Newcastle upon Tyne, UK.

出版信息

Commun Chem. 2025 Apr 9;8(1):111. doi: 10.1038/s42004-025-01501-6.

DOI:10.1038/s42004-025-01501-6
PMID:40204983
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11982232/
Abstract

The discovery of targeted covalent inhibitors is of increasing importance in drug discovery. Finding efficient covalent binders requires modulation of warhead reactivity and optimisation of warhead geometry and non-covalent interactions. Uncoupling the contributions that these factors make to potency is difficult and best practice for a testing cascade that is pragmatic and informative is yet to be fully established. We studied the structure-reactivity-activity relationships of a series of analogues of the EGFR inhibitor poziotinib with point changes in two substructural regions as well as variations in warhead reactivity and geometry. This showed that a simple probe displacement assay that is appropriately tuned in respect of timing and reagent concentrations can reveal structural effects on all three factors: non-covalent affinity, warhead reactivity and geometry. These effects include the detection of potency differences between an enantiomeric pair that differ greatly in their activity and their capacity to form a covalent bond. This difference is rationalised by X-ray crystallography and computational studies and the effect translates quantitatively into cellular mechanistic and phenotypic effects.

摘要

在药物研发中,靶向共价抑制剂的发现变得越来越重要。寻找高效的共价结合剂需要调节弹头反应性,并优化弹头几何结构和非共价相互作用。区分这些因素对效力的贡献很困难,且尚未完全确立一个实用且信息丰富的测试级联的最佳实践方法。我们研究了一系列表皮生长因子受体(EGFR)抑制剂波齐替尼类似物的结构-反应性-活性关系,这些类似物在两个亚结构区域有位点变化,同时弹头反应性和几何结构也有所不同。结果表明,一个在时间和试剂浓度方面经过适当调整的简单探针置换试验,可以揭示对所有三个因素的结构影响:非共价亲和力、弹头反应性和几何结构。这些影响包括检测对映体对之间的效力差异,它们在活性和形成共价键的能力方面有很大差异。通过X射线晶体学和计算研究对这种差异进行了合理化解释,并且这种影响定量地转化为细胞机制和表型效应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358b/11982232/78d81bd8cb1f/42004_2025_1501_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358b/11982232/a81da8db109e/42004_2025_1501_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358b/11982232/e2060ebf4c64/42004_2025_1501_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358b/11982232/8f7383fccdeb/42004_2025_1501_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358b/11982232/56b9b00048d8/42004_2025_1501_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358b/11982232/0957bb5aef9f/42004_2025_1501_Sch1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358b/11982232/4449300e7440/42004_2025_1501_Sch2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358b/11982232/30368a78799d/42004_2025_1501_Sch3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358b/11982232/38e12e0b5393/42004_2025_1501_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358b/11982232/9723ca669389/42004_2025_1501_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358b/11982232/f6b4ce5cb6e2/42004_2025_1501_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358b/11982232/78d81bd8cb1f/42004_2025_1501_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358b/11982232/a81da8db109e/42004_2025_1501_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358b/11982232/e2060ebf4c64/42004_2025_1501_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358b/11982232/8f7383fccdeb/42004_2025_1501_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358b/11982232/56b9b00048d8/42004_2025_1501_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358b/11982232/0957bb5aef9f/42004_2025_1501_Sch1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358b/11982232/4449300e7440/42004_2025_1501_Sch2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358b/11982232/30368a78799d/42004_2025_1501_Sch3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358b/11982232/38e12e0b5393/42004_2025_1501_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358b/11982232/9723ca669389/42004_2025_1501_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358b/11982232/f6b4ce5cb6e2/42004_2025_1501_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/358b/11982232/78d81bd8cb1f/42004_2025_1501_Fig8_HTML.jpg

相似文献

1
Factors affecting irreversible inhibition of EGFR and influence of chirality on covalent binding.影响表皮生长因子受体不可逆抑制的因素及手性对共价结合的影响。
Commun Chem. 2025 Apr 9;8(1):111. doi: 10.1038/s42004-025-01501-6.
2
Classifying covalent protein binders by their targeted binding site.
Bioorg Med Chem Lett. 2025 Mar 1;117:130067. doi: 10.1016/j.bmcl.2024.130067. Epub 2024 Dec 10.
3
Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance.共价 EGFR 抑制剂分析揭示了可逆相互作用对药物效力和耐药机制的重要性。
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):173-8. doi: 10.1073/pnas.1313733111. Epub 2013 Dec 17.
4
Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity.拓展兵工厂:预测和调整共价弹头反应性。
J Chem Inf Model. 2017 Dec 26;57(12):3124-3137. doi: 10.1021/acs.jcim.7b00553. Epub 2017 Nov 21.
5
Binding Mode Prediction and Virtual Screening Applications by Covalent Docking.基于共价对接的结合模式预测与虚拟筛选应用
Methods Mol Biol. 2021;2266:73-88. doi: 10.1007/978-1-0716-1209-5_4.
6
COVALENT INHIBITION OF BOTULINUM NEUROTOXIN A - EXPLORATION OF WARHEAD REACTIVITY AND FUNCTION USING A BIFUNCTIONAL APPROACH.利用双功能方法研究弹头反应性和功能的肉毒毒素 A 共价抑制。
Toxicon. 2021 Jan;190(Suupl 1):S72-S73. Epub 2021 Jan 16.
7
Integrated Covalent Drug Design Workflow Using Site Identification by Ligand Competitive Saturation.基于配体竞争饱和的靶标鉴定的整合共价药物设计工作流程。
J Chem Theory Comput. 2023 May 23;19(10):3007-3021. doi: 10.1021/acs.jctc.3c00232. Epub 2023 Apr 28.
8
Covalent Docking in Drug Discovery: Scope and Limitations.共价对接在药物发现中的应用:范围与局限性。
Curr Pharm Des. 2020;26(44):5684-5699. doi: 10.2174/1381612824999201105164942.
9
Discovering covalent cyclic peptide inhibitors of peptidyl arginine deiminase 4 (PADI4) using mRNA-display with a genetically encoded electrophilic warhead.利用带有基因编码亲电弹头的mRNA展示技术发现肽基精氨酸脱亚氨酶4(PADI4)的共价环肽抑制剂。
Commun Chem. 2024 Dec 19;7(1):304. doi: 10.1038/s42004-024-01388-9.
10
A study of the reactivity of S-F containing warheads with nucleophilic amino-acid side chains under physiological conditions.一项关于含硫氟弹头在生理条件下与亲核氨基酸侧链反应活性的研究。
Org Biomol Chem. 2017 Nov 22;15(45):9685-9695. doi: 10.1039/c7ob02028g.

引用本文的文献

1
Covalent chemical probes.共价化学探针
Commun Chem. 2025 Aug 29;8(1):266. doi: 10.1038/s42004-025-01652-6.
2
Profiling and Optimizing Targeted Covalent Inhibitors through EGFR-Guided Studies.通过表皮生长因子受体(EGFR)导向研究对靶向共价抑制剂进行分析和优化
J Med Chem. 2025 Aug 28;68(16):17917-17932. doi: 10.1021/acs.jmedchem.5c01661. Epub 2025 Aug 13.

本文引用的文献

1
Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update.新兴与重现的靶向共价抑制剂弹头:更新。
J Med Chem. 2024 May 23;67(10):7668-7758. doi: 10.1021/acs.jmedchem.3c01825. Epub 2024 May 6.
2
Targeting Cytotoxic Agents through EGFR-Mediated Covalent Binding and Release.通过 EGFR 介导的共价结合和释放靶向细胞毒性剂。
J Med Chem. 2023 Sep 14;66(17):12324-12341. doi: 10.1021/acs.jmedchem.3c00845. Epub 2023 Aug 30.
3
Advances in covalent drug discovery.共价药物发现的进展。
Nat Rev Drug Discov. 2022 Dec;21(12):881-898. doi: 10.1038/s41573-022-00542-z. Epub 2022 Aug 25.
4
Design of a "Two-in-One" Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites.“二合一”变构型选择性表皮生长因子受体抑制剂的设计:占据变构和正位结合位点。
J Med Chem. 2022 Jan 27;65(2):1370-1383. doi: 10.1021/acs.jmedchem.1c00848. Epub 2021 Oct 20.
5
Discovery of a Covalent Inhibitor of KRAS (AMG 510) for the Treatment of Solid Tumors.发现 KRAS(AMG 510)共价抑制剂用于治疗实体瘤。
J Med Chem. 2020 Jan 9;63(1):52-65. doi: 10.1021/acs.jmedchem.9b01180. Epub 2019 Dec 24.
6
Structure-based design of targeted covalent inhibitors.基于结构的靶向共价抑制剂设计。
Chem Soc Rev. 2018 Jun 5;47(11):3816-3830. doi: 10.1039/c7cs00220c.
7
Diffraction-geometry refinement in the DIALS framework.DIALS框架中的衍射几何精修
Acta Crystallogr D Struct Biol. 2016 Apr;72(Pt 4):558-75. doi: 10.1107/S2059798316002187. Epub 2016 Mar 30.
8
Covalent protein modification: the current landscape of residue-specific electrophiles.共价蛋白质修饰:残基特异性亲电试剂的现状。
Curr Opin Chem Biol. 2015 Feb;24:18-26. doi: 10.1016/j.cbpa.2014.10.021. Epub 2014 Nov 11.
9
Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.发现一种有效的、选择性的 EGFR 抑制剂(AZD9291),对敏感突变和 T790M 耐药突变均有效,并且能避免野生型受体的影响。
J Med Chem. 2014 Oct 23;57(20):8249-67. doi: 10.1021/jm500973a. Epub 2014 Oct 1.
10
Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors.AZD8931的发现,一种对表皮生长因子受体(EGFR)、人表皮生长因子受体2(HER2)和人表皮生长因子受体3(HER3)信号传导具有同等效力的可逆抑制剂。
ACS Med Chem Lett. 2013 May 31;4(8):742-6. doi: 10.1021/ml400146c. eCollection 2013 Aug 8.